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Abstract 
Levosimendan is a calcium sensitizer and ATP-dependent potassium channel opener which 
exerts sustained hemodynamic, symptomatic and organ-protective effects. It is registered for 
the treatment of acute heart failure, and when inotropic support is considered appropriate. In 
the past fifteen years, levosimendan has been widely used in clinical practice, and has also 
been tested in clinical trials to stabilize at-risk patients undergoing cardiac surgery. Recently, 
three randomized, placebo-controlled, multicenter studies (LICORN, CHEETAH and LEVO-
CTS) have been published reporting on the peri-operative use of levosimendan in patients 
with compromised cardiac ventricular function. Taken together, many smaller trials 
conducted in the past suggested beneficial outcomes with levosimendan in peri-operative 
settings. In contrast, the latest three studies were neutral or inconclusive. In order to 
understand the reasons for such dissimilarity, a group of experts from Austria, Belgium, 
Finland, France, Germany, Italy, Switzerland, and Russia, including investigators from the 
three most recent studies, met to discuss the study results in the light of both the previous 
literature and current clinical practice. Despite the fact that the null hypothesis could not be 
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ruled out in the recent multicenter trials, we conclude that levosimendan can still be viewed as 
a safe and effective inodilator in cardiac surgery.  
 
 
 
 
Short title: latest trials on levosimendan in cardiac surgery  
 
Key words: cardiac surgery; clinical trials; levosimendan; systematic review; opinion paper. 
 
1. Introduction 
Peri-operative mortality is reported to be as low as 1–4% in the general elective surgery 
population.1 However, in patients with postoperative low cardiac output syndrome (LCOS), 
mortality is considerably higher.2 In addition to higher mortality, LCOS predisposes patients 
to postoperative myocardial injury, renal failure, and prolonged intensive care unit and 
hospital stay.3 Several baseline factors, such as preoperatively reduced left (and/or right) 
ventricular function or recent myocardial infarction predispose patients to LCOS.4 The type of 
surgery also affects the postoperative risk profile; coronary artery bypass grafting (CABG) 
alone has a more benign outcome than, for example, the combination of CABG and a valve 
replacement.5   
 LCOS is managed with inotropic agents and/or mechanical cardiac assist devices such 
as an intra-aortic balloon pump (IABP). Even so, short-term mortality is greatly elevated 
versus non-LCOS comparators.6 Moreover, the inotropic agents traditionally used in this 
setting have conspicuous adverse effects or incompletely defined safety profiles.7 
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 Levosimendan is a calcium sensitizer and ATP-dependent potassium channel opener 
with positive inotropic, vasodilatory and cardioprotective properties.8 The drug binds to 
cardiac troponin C in a calcium-dependent manner9,10 which mediates the positive inotropic 
effect by increasing the calcium sensitivity of myocytes. The vasodilatory effect is due to the 
opening of ATP-sensitive potassium channels in vascular smooth muscle resulting in its 
relaxation. By opening mitochondrial ATP-sensitive potassium channels in cardiomyocytes 
the drug also exerts a cardioprotective effect. In addition, inhibition of phosphodiestherase III 
by levosimendan has been also proposed to have a role in its pharmacodynamics effects.11 
 Levosimendan has been in clinical use for 15 years. In addition to its original indication 
for acutely decompensated heart failure, it has also been used to stabilize patients undergoing 
cardiac surgery. Abundant literature from exploratory studies supports the rationale for its use 
in this indication,12 and this is also supported by its benign effect on kidney function.13 
 Recently, three randomized, placebo-controlled, multicenter studies were published on 
the peri-operative use of levosimendan: LICORN,14 CHEETAH,15 and LEVO-CTS.16 In 
contrast to the many preceding smaller trials which, either individually or as a whole, 
produced a promising image of levosimendan in peri-operative settings, these latest three 
studies were either neutral or inconclusive. 
 A group of experts from eight European countries (Austria, Belgium, Finland, France, 
Germany, Italy, Switzerland, and Russia), including investigators from the three most recent 
studies on the pre-, peri-, and postoperative use of levosimendan, met on 20 April 2017 in 
occasion of the EACTA annual congress in Berlin, Germany, to discuss the recent study 
results in the light of both the previous literature and current clinical practice. The present 
paper was created from the proceedings of that discussion. 
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2. Previous relevant studies on the use of levosimendan in cardiac surgery 
Levosimendan has been studied in >40 clinical trials in cardiac surgery. Earlier studies 
suggested that it could prevent the development of LCOS and be effective in treating 
postoperative LCOS (see BOX 1). The level of proof, however, remained low despite a meta-
analysis that suggested a survival benefit in patients with low pre-operative ejection 
fraction.17 Indications of renal-protective effects in this setting have also been reported in 
retrospective analyses.18,19 
The individual and aggregate findings of the 14 studies in cardiac surgery patients with 
low left ventricular ejection fraction (LVEF) examined by Harrison et al.17 in their meta-
analysis are reported in Figure 1, and the results of the contributing studies are summarized 
briefly in Table 1.20-33  
In total, Harrison and coworkers took into consideration data from 1155 patients (84 
deaths) and the overall effect of levosimendan vs comparator was significant (p=0.008). 
Visual inspection of the funnel plot for the primary outcome of mortality was not suggestive 
of significant publication bias. However, removal of either of the two studies by Levin and 
coworkers25,26  made the overall estimated effect of levosimendan on mortality insignificant. 
For the sake of completeness, we report that, in addition to the 14 papers considered by 
Harrison et al., other relevant studies conducted on levosimendan in surgical patients are 
those by Severi et al.34 and Lomivorotov et al.35 on levosimendan versus IABP; the trials by 
Baysal et al.36 and Erb et al.37 on renal outcome and organ dysfunction, respectively; and the 
randomized pilot study on prophylactic use of levosimendan by Anasthasiadis et al.38 
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3. The three most recent studies 
Three larger clinical studies have recently been conducted with levosimendan in patients 
undergoing cardiac surgery. All three were randomized, placebo-controlled, multicenter 
studies. The LICORN and CHEETAH studies were investigator-initiated studies, whereas 
LEVO-CTS was a phase 3 regulatory study (see BOX 2). Broad outlines of the study designs 
and their primary findings are given below. 
 
3.1. LICORN 
The LICORN trial (Levosimendan on Low Cardiac Output Syndrome in Patients With Low 
Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary 
Bypass; NCT02184819) assessed the efficacy of a pre-operative infusion of levosimendan in 
reducing postoperative LCOS in patients with poor LVEF undergoing CABG.14 A cohort of 
336 patients with LVEF ≤40% undergoing CABG was recruited from 13 French hospitals. 
The study drug was started after induction of anesthesia and infused over a period of 24 h at a 
rate of 0.1 µg/kg/min. Postoperative LCOS was evaluated using a composite criterion 
comprising (1) need for inotropic agents beyond 48 h following discontinuation of the study 
drug; (2) need for postoperative mechanical assist devices or failure to wean from these 
devices when inserted pre-operatively; and (3) need for renal replacement therapy.  
The primary endpoint was observed in 87/167 patients (52%) in the levosimendan 
group, compared with 101/168 (61%) in the placebo group (absolute risk reduction -7%, 95% 
confidence interval [CI]: -17% to +3%, p=0.15). Of the secondary endpoints, the duration of 
catecholamine treatment was shorter in the levosimendan group: 3.2±3.6 versus 4.1±4.3 days 
(p=0.021). However, no adjustment was made for multiple comparisons, and this result 
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should be considered exploratory. There were no statistically significant inter-group 
differences in mortality or length of ICU stay.  
The lack of statistical significance in the composite primary endpoint was likely 
contributed to by the fact that the observed event rate in the placebo arm was lower than that 
anticipated (61% vs 65%); it was anticipated also that the prevalence rate would be reduced to 
50% in the levosimendan group, but the prevalence actually observed was 52% in the 
intention-to-treat population (vs. 51% in the per-protocol population). LICORN was powered 
according to an expectation of an absolute risk reduction of 15%. The point estimate actually 
recorded was 7% and favored levosimendan but the 95% CI included a reduction of 17% 
(range –17% to +3%). The observed effect was less than that anticipated by the study 
hypothesis; however, the study was underpowered to definitely exclude a meaningful 
beneficial effect of levosimendan on the primary composite outcome.  
 
3.2. CHEETAH  
In the CHEETAH (Levosimendan to Reduce Mortality in High Risk Cardiac Surgery 
Patients; NCT00994825) trial, levosimendan or placebo was administered to cardiac surgery 
patients, who, according to predefined criteria, developed postoperative LCOS.15 In total, 
1000 patients were scheduled to be included and the primary endpoint was 30-day mortality. 
The study was performed in 14 centers in Italy, Russia and Brazil but was stopped for futility 
after 506 patients had been enrolled. A total of 248 patients received levosimendan and 258 
received placebo. The mean infusion rate and duration of levosimendan were 0.07 µg/kg/min 
for 33 h, and the median EF was 50% in both groups, with 11% of patients having an EF of < 
25%. There was no significant difference in 30-day mortality between the levosimendan and 
placebo groups: 32 patients (12.9%) versus 33 (12.8%); absolute risk difference 0.1 
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percentage points; 95% CI −5.7 to +5.9 percentage points; P=0.97). There were no significant 
between-group differences in other endpoints and no difference in the rates of adverse events 
(hypotension or arrhythmias). 
It should be noted that, in the report of the CHEETAH study, preparation of the study 
drug was described as follows:15 “levosimendan was diluted as 12.5 mg in 100 ml of 5% 
glucose”. This is at variance with the summary of product characteristics guidance, according 
to which one vial of Simdax (12.5 mg levosimendan concentrate for i.v.) should be diluted in 
at least 250 mL of 5% glucose solution (1:50). There is a risk of precipitation if smaller 
diluent volumes are used and this exposes the patient to unpredictable dosing (i.e. receipt of 
less than the intended dose). 
 
 
3.3 LEVO-CTS  
This study (Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing 
Cardiac Surgery Requiring Cardiopulmonary Bypass; NCT02025621) was a Phase III clinical 
trial sponsored by TENAX Therapeutics Inc., run by Duke University (Durham, NC, USA) 
and configured to support a marketing authorization in the U.S. and Canada for 
levosimendan.16 The study design and objectives were discussed beforehand and agreed with 
the U.S. Food and Drug Administration (FDA).  
The study population consisted of 882 patients with low pre-operative LVEF 
(EF<35%) undergoing scheduled or urgent cardiac surgery (CABG and/or mitral valve 
surgery with or without involvement of other valves). All patients were considered at risk of 
developing postoperative LCOS. Levosimendan (0.2 µg/kg/min for 60 min, followed by 0.1 
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µg/kg/min for 23 h) or placebo was started at the induction of anesthesia to assess whether the 
drug would decrease the development of LCOS and its detrimental consequences.  
The study, conducted at 70 sites in Canada and the U.S., demonstrated no statistically 
robust treatment effect on the composite primary endpoint of death, peri-operative myocardial 
infarction and need for renal replacement therapy or a mechanical ventricular assist device. 
However, there were fewer deaths in the levosimendan group: 20/428 (4.7%) versus 30/421 
(7.1%), oddes ratio 0.64, 95% CI 0.37–1.13 (p=0.12). In addition, the levosimendan-treated 
patients experienced statistically significantly fewer LCOS events (78 vs 108; p=0.007) and 
needed less inotropic support at or beyond 24 h after initiation of infusion (235 vs. 264; 
p=0.02). Cardiac index also improved more in levosimendan-treated patients (2.9±0.6 vs 
2.7±0.7 L/min/m2; p<0.001). Hypotension and atrial arrhythmias were recorded as adverse 
events with similar frequency in both study groups.  
The LEVO-CTS investigators are conducting post-hoc analyses in relevant 
predetermined sub-settings (e.g. CABG with or without accompanying valve surgery). So far, 
they have shown data suggesting that in those patients in whom only CABG was performed, 
mortality was significantly lower in the levosimendan group: 6/284 (2.1%) versus 22/279 
(7.9%), hazard ratio 0.259, 95% CI 0.105–0.640 (p=0.0016) (Figure 2). 
 
4. Interpretation of the data 
4.1. Efficacy 
The hypotheses tested in all three studies were not affirmed, and the primary endpoints did 
not differ significantly between the levosimendan and control arms.  
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It must be noted that the endpoints used in LEVO-CTS and LICORN were 
experimental ones. Similar endpoints have not been used in earlier studies. The LEVO-CTS 
primary endpoints were agreed with the FDA, which required the inclusion of clinical events. 
This notwithstanding, encouraging evidence of efficacy emerged from LEVO-CTS: the lower 
incidence of LCOS, lesser need for inotropic support by cathecolamines, and improvement in 
CI indicate that levosimendan exhibited efficacy. In CHEETAH, only suggestive signs of 
improved hemodynamics were noted but the dose of levosimendan in that study was smaller 
than those in LEVO-CTS or LICORN or in previous studies in cardiac surgery. The subgroup 
data from LEVO-CTS (the supplementary material of the publication is available via 
http://www.nejm.org/doi/full/10.1056/NEJMoa1616218) suggest that levosimendan may be 
more effective in patients in whom only the CABG procedure is performed (and ineffective in 
valve replacement patients). Also, in line with earlier data, patients with the lowest EF before 
surgery may benefit most from the treatment. However, this was not observed in the LICORN 
study, in which no statistically significant difference was found with respect to the primary 
endpoint between patients with LVEF<30% or between 30% and 40%. 
Although the duration of treatment with inotropic agents was an outcome variable, the 
LICORN and CHEETAH protocols do not give details of hemodynamic monitoring and 
specifically when inotrope treatment should be stopped. With regard to the limited efficacy of 
levosimendan, the regimen used in the trials can be questioned. Both LEVO-CTS and 
LICORN used a 0.1 µg/kg/min infusion for 24 h without bolus, in conformity with recent 
recommendations by experts in cardiovascular anesthesia.12 Several previous studies have 
used infusion rates of 0.2 µg/kg/min with variable bolus doses. Higher doses may have 
produced greater hemodynamic effects, but at the expense of a more potent vasodilatation and 
consequent hypotension 
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In the LICORN trial, inodilatators and inopressors were analyzed together as 
‘catecholamines’ irrespective of their predominant hemodynamic effect and no doses for the 
respective drugs were reported. Consequently it cannot be ruled out that patients with a severe 
postoperative LCOS receiving high doses of epinephrine and milrinone, and those needing 
only small doses of norepinephrine on the second day after surgery were both classified as 
‘catecholamine-dependent’. 
One additional observation regarding LEVO-CTS and LICORN is that levosimendan 
therapy was started very shortly before surgery; accordingly, there was only a short time 
during which levosimendan could exert any preconditioning effect. In some previous studies, 
and in clinical practice, levosimendan has been administered for up to 24 h before the start of 
surgery.26,30  
Finally, in the CHEETAH trial the majority of patients received a relatively low dose of 
levosimendan whilst already being treated with high doses of epinephrine and dobutamine. 
Pre-treatment with beta-mimetic drugs has been shown to reduce the inotropic effect of 
levosimendan in vitro39 and thereby may also reduce its benefits in vivo, as shown by Bonios 
et al.40 in a trial comparing the event-free survival of patients treated with levosimendan, 
dobutamine, or their combination. 
 
4.2. Safety 
Safety was not identified as a concern in any of these three studies: there was no significant 
excess of arrhythmias or hypotension and no increase in mortality in levosimendan-treated 
patients. In fact, mortality was numerically lower in levosimendan-treated patients in LEVO-
CTS.16 
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These findings are fully consistent with the data on safety and adverse events reported 
in most of the previous studies (as collected in a systematic review and meta-analysis by 
Landoni et al.41) and confirm levosimendan as the safest agent among the family of inotropes 
and inodilators which include, among others, dobutamine and milrinone.42 When an inotrope 
is needed, the safety profile of the chosen agent should be an important selection criterion. 
In addition, levosimendan has a unique mechanism of action and pharmacokinetics. 
The sensitization of myofilaments to calcium supposes that the inotropic effects occurs 
without (or with minimal) increase in myocardial oxygen consumption. The prolonged effect 
which lasts for several days,43,44 contrasts with the on-off action of dobutamine. These 
specificities may prove useful in selected patients and are a major reason to keep 
levosimendan in the armamentarium of physicians in charge of patients with cardiac 
dysfunction. 
 
 
5. Discussion  
While the many smaller trials conducted in the past produced as a whole a promising image of 
levosimendan in peri-operative settings, the data from the latest (and larger) three studies did 
not support the hypotheses tested.  
Instead of advocating the ‘small-study effect’, i.e. the trend for smaller studies to show 
larger treatment effects,45 every study should be evaluated fairly, as large studies can be 
imprecise, just as small ones can be precise.46 
 Indeed, in small monocentric trials focused on a few endpoints in very specific clinical 
settings, the researchers are in a more controlled situation than in a multicenter trial in the 
field. In addition, in clinical settings where there are local variations in therapeutic approaches 
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and tailored strategies (such as, for example, in mitral valve surgery47), multicenter trials add, 
by definition, statistical noise to many endpoints: variations in pharmacologic and non-
pharmacologic parameters have the potential to impair the statistical power and obscure 
meaningful effects. Multicenter studies in fields such as perioperative LCOS, where multiple 
sources of heterogeneity exist (e.g. symptoms, etiologies, comorbidities, co-medications and 
center-specific treatment practices), encounter such problems.  
 All the above notwithstanding, we have noticed that studies of all sizes on 
levosimendan have produced some common and consistent findings in terms of safety. 
Levosimendan is safe and well tolerated in patients undergoing cardiac surgery with 
cardiopulmonary bypass who have low LVEF and are at risk of the development of 
postoperative LCOS. This safety finding, and especially the lack of any deterioration in 
survival, is particularly noteworthy given that many of the patients in all three trials had 
already been treated with a range of other pressor and/or inotropic drugs. The non-attainment 
of the study hypotheses in these three recent trials does not rule out the fact that levosimendan 
might be effective in selected patients undergoing cardiac surgery. The LEVO-CTS study, as 
the largest of these trials, confirms that a prophylactic infusion of levosimendan  started 
immediately before surgery reduces LCOS in a heterogeneous population of cardiac surgery 
patients with reduced LVEF. The post-hoc analyses further suggest that this drug may be 
especially useful in patients undergoing CABG with reduced LVEF, but not in those 
undergoing a valve surgery. A recent meta-analysis, including also the latest trials, confirms 
that levosimendan had a significant effect on mortality only when used in case of severe 
perioperative cardiovascular dysfunction (LVEF ≤ 30%) in patients receiving cardiac 
surgery.48 No comparable data are available for any other drugs with inotropic properties; on 
the contrary, traditional inotropes are considered to have detrimental effects on outcome.42 
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In addition, levosimendan has been shown to reduce elevated right-sided pressures in 
various clinical situations.49-51 Preoperative administration of levosimendan decreased 
pulmonary artery pressure significantly in patients with right ventricular dysfunction and 
pulmonary hypertension.52 As pulmonary hypertension is an important prognostic factor in 
cardiac surgery associated with increased morbidity and mortality,53 levosimendan´s efficacy 
could be pronounced in this subgroup and we warmly suggest to explore this setting. 
Finally, it must be registered that in many studies, including relatively large regulatory 
clinical trials, levosimendan was administered in addition to standard of care (i.e. other 
vasoactive drugs) according to prevailing practice at individual study centers. It would be 
instructive to perform a post-hoc analysis of those data to explore whether combinations of 
levosimendan with dobutamine or norepinephrine are beneficial.  
 
 
 
6. Conclusions 
Taking all the available data into consideration, including the experience of the three 
most recent studies, our conclusion is that levosimendan is a safe and effective agent for the 
treatment of patients undergoing cardiac surgery and in need of inotropic support (see BOX 
3). However, the magnitude of effect of this agent is not as large as previously thought and 
three large multi-center trials could not rule out their null hypothesis. For this reason 
levosimendan cannot be at the moment recommended for routine use in all cardiac surgery 
settings. Further in-depth assessment of the utility of levosimendan will require additional 
trials in closely defined patient populations with study designs that mitigate, to the fullest 
extent possible, any influence of methodological variations in patient management.  
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Legends to the figures 
 
Figure 1. Meta-analysis of data from 14 randomized controlled trials of peri-operative 
levosimendan in cardiac surgery patients (n=1155) indicates that levosimendan therapy is 
associated with reduced mortality, with the greatest benefit observed in patients with reduced 
LVEF. From Harrison and coworkers.17  
 
Figure 2. Ninety-day mortality among patients in the LEVO-CTS trial in (A) the whole study 
(n=849) and (B) the subgroup of isolated CABG patients (n=563). In the latter, mortality was 
significantly lower in the levosimendan arm than in the placebo arm. From supplemental 
materials in Mehta and coworkers.16 
 
Figure 3. Meta-analysis of clinical trials on levosimendan versus control in cardiac surgery 
patients with long term and thirty-day mortality as primary outcome: effects of levosimendan 
when used in case of severe perioperative cardiovascular dysfunction (LVEF ≤ 30%). 
Sensitivity analysis as in the supplemental material of Lee and coworkers.48 
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BOX 1.  Previous relevant studies on the use of levosimendan in cardiac surgery 
• Over 40 clinical trials were run on the use of levosimendan  in cardiac surgery; 
• Earlier studies suggested that levosimendan could prevent the development of LCOS and 
could be effective in treating postoperative LCOS;  
• Meta-analyses suggested a reduction of mortality, significant when levosimendan is used in 
case of severe perioperative cardiovascular dysfunction (LVEF ≤ 30%); 
• Indications of favorable renal effects in this setting have also been reported.  
 
 
BOX 2. The three most recent studies on levosimendan in carac surgery 
• LICORN - Levosimendan on Low Cardiac Output Syndrome in Patients With Low 
Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary 
Bypass trial (NCT02184819) assessing the efficacy of a pre-operative infusion of 
levosimendan in reducing postoperative LCOS in patients with poor LVEF undergoing 
CABG; 
• CHEETAH- Levosimendan to Reduce Mortality in High Risk Cardiac Surgery 
Patients trial (NCT00994825) assessing the effect of levosimendan on cardiac surgery 
patients who developed postoperative LCOS; 
• LEVO-CTS - Levosimendan in Patients with Left Ventricular Systolic Dysfunction 
Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass, Phase III clinical trial 
(NCT02025621) assessing the effct of levosimendan on patients with low pre-operative 
LVEF (EF<35%) undergoing scheduled or urgent cardiac surgery. 
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BOX 3. Consensus on efficacy and safety of levosimendan in operative settings 
Taking all the available data into consideration, including the experience of these three recent 
studies:  
•  levosimendan is a safe agent for the treatment of patients undergoing cardiac surgery and 
in need of inotropic support, despite the three large multi-center trials could not rule out 
their null hypothesis; 
•  levosimendan is an effective agent as it regards hemodynamic support; 
•  statistically significant mortality benefit seems to be limited to sub-groups, such as the 
isolated CABG procedures, and the low EF patients; 
•  further in-depth assessment of the utility of levosimendan will require additional trials in 
closely defined patient populations with study designs that mitigate to the fullest extent 
possible any influence of methodological variation. 
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 Table I: Studies on the use of levosimendan in peri-operative settings included in the meta-analysis by Harrison et al.17 
first author, 
year of 
publication (ref) 
Settings Trial design LS dose Start of  
treatment 
Comparator Patients in 
LS arm vs 
comparator  
Primary 
end-points/evaluations 
Secondary 
end-points/evaluations 
Al-Shawaf 
2006.20 
Postoperative LCOS 
(within 12 h) in pts with 
type 2 DM and 
preoperative  LVEF < 
35%, to whom CABG 
was performed 
Randomized 
open-label 
12 mcg/kg 
bolus + 0.1-
0.2 
mcg/kg/min 
for 24 h 
Within 12 
h post 
surgery 
Milrinone 50 
mcg/kg 
bolus + 0.3-
0.5 
mcg/kg/min 
for 24 h 
14 vs. 16 Superior hemodynamic effects 
(cardiac index, mixed venous 
saturation) with LS  
No difference in insulin 
requirements,  
Time in ventilator & ICU 
shorter with LS 
Alvarez 
2005.21 
Post-operative cardiac 
index < 2.5 l/min/m2 in 
pts to whom CABG was 
performed 
Randomized 
open-label 
12 mcg/kg 
bolus + 0.2 
mcg/kg/min 
for 24 h 
Post 
surgery 
Dobutamine 
7.5 
mcg/kg/min 
for 24 h 
15 vs. 15 Cardiac index and heart rate 
increased, and mean arterial 
pressure, systemic and 
pulmonary vascular index 
decreased significantly in LS 
group  
 
Alvarez  
2006.22 
Postoperative LCOS 
(within 4 h) in pts to 
whom CABG or valvular 
surgery was performed 
Randomized 
open-label 
12 mcg/kg 
bolus + 0.2 
mcg/kg/min 
for 24 h 
Within 4 h 
post 
surgery 
Dobutamine 
7.5 
mcg/kg/min 
for 24 h 
25 vs. 25 More pronounced heart rate and 
cardiac index increase, and 
more pronounced decrease in 
systemic vascular resistance in 
LS group 
The hemodynamic effects 
lasted beyond study drug 
infusion period only in LS 
group 
DeHert 
2007.23 
Patients with 
preoperative LVEF 
≤30% and to whom 
CABG and or valvular 
surgery was performed 
Randomized 
open-label; 
assessment 
of outcomes 
by blinded 
observers 
0.1 
mcg/kg/min 
for 19 h 
Immediatel
y after 
release of  
aortic 
crossclamp 
Milrinone 
0.5 
mcg/kg/min 
for 83 h 
15 vs. 15 Stroke volume increased 
initially similarly, but the effect 
lasted longer in LS group 
Secondary inotrope and 
vasoconstrictor need lower 
in LS group 
Tracheal intubation time 
shorter in LS group 
Eriksson 
2009.24 
Patients with 3-vessel 
coronary disease and  
LVEF < 50% to whom 
CABG was performed 
Randomized  
double-blind 
12 mcg/kg 
bolus + 0.2 
mcg/kg/min 
for 24 h 
Immediatel
y after 
induction 
of 
anesthesia 
Placebo 30 vs. 30 Primary weaning from 
cardiopulmonary bypass 
successful in 73% vs. 33% in 
LS and placebo groups, 
respectively; p=0.002 
Need for additional 
inotropic or 
mechanical therapy lower 
in LS group 
Levin  
2009.25 
Postoperative LCOS 
(within 6 h) in pts with 
preoperative  LVEF < 
25%, to whom CABG 
was performed 
Randomized 
open-label 
10 mcg/kg 
bolus + 0.1 
mcg/kg/min 
for 24 h 
Within 6 h 
post 
surgery 
Dobutamine 
5-12.5 
mcg/kg/min 
for 24 h 
127 vs. 
126 
Post-operative mortality lower 
in LS group (7.1% vs. 15.9%; 
p<0.05) 
Lower need for secondary 
inotropes (14.2 vs. 32.5%), 
vasopressors (17.3 vs. 
43.6%) and intra-aortic 
balloon pump (3.1 vs. 
14.2%); p<0.05 for all 
Levin 
2012.26 
Patients with 
preoperative LVEF 
<25% undergoing CABG  
Randomized 
open-label 
10 mcg/kg 
bolus + 0.1 
mcg/kg/min 
for 24 h 
24 h before 
surgery 
Placebo 127 vs. 
125 
Postoperative LCOS (7.1% vs. 
20.8%; p<0.05) and mortality 
(3.9% vs. 12.8%; p<0.05) lower 
in LS group 
Difficult weaning from 
cardiopulmonary bypass, 
need for secondary 
inotropes and vasopressors 
and need for intra-aortic 
AC
CE
PT
ED
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. 
 ballon pump less frequent 
in LS group 
Lomivorotov 
2011.27 
40 consecutive patients 
with LVEF<35%, who 
underwent coronary 
artery 
bypass grafting, were 
included 
Randomized 
open-label 
12 mcg/kg 
bolus + 0.1 
mcg/kg/min 
for 24 h 
Immediatel
y after 
induction 
of 
anesthesia 
Intra-aortic 
balloon 
pump 16-18 
h before 
operation 
20 vs. 20 Cardiac index significantly 
higher 5 min after CBP, at the 
end of the operation, 2 and 
4 h after perfusion in LS group 
Toponin I  lower at 6 h 
after the operation and  
ICU stay in LS group 
Järvelä 
2008.28 
Patients undergoing 
aortic 
valve surgery with or 
without CABG 
Randomized 
double-blind 
0.2 
mcg/kg/min 
for 24 h 
Immediatel
y after 
induction 
of 
anesthesia 
Placebo 12 vs. 12 LVEF maintained in LS group, 
but decreased in control group 
after operation 
LS prevented 
postoperative decreases in 
mixed venous saturation 
and central venous oxygen 
saturation 
Lahtinen 
2011.29 
Patients undergoing 
CABG or valve 
operation or both 
Randomized 
double-blind 
24 mcg/kg 
bolus + 0.2 
mcg/kg/min 
for 24 h 
Immediatel
y after 
induction 
of 
anesthesia 
Placebo 99 vs. 101 Heart failure defined as 
cardiac index <2.0 l/min/m2 or 
failure to wean from CPB  
15% vs. 58% in LS and placebo 
groups, respectively; p<0.001 
Rescue inotrope and intra-
aortic ballon pump needed 
less, but vasopressor more 
in LS group 
Leppikangas 
2011.30 
Patients undergoing 
aortic 
valve surgery and 
CABG; additionally 
preoperative LVEF<50% 
or LV thickness > 12 
mm 
Randomized 
double-blind 
12 mcg/kg 
bolus + 0.2 
mcg/kg/min 
for 24 h 
24 h before 
surgery 
Placebo 12 vs. 12 Cardiac index and stroke 
volume index (SI) higher in LS 
group) for the 4 day 
postoperative period  
 
Momeni 
2011.31 
Pediatric study on 
patients between 0 and 5 
y.o. requiring inotropic 
support for corrective 
congenital heart surgery 
under cardio-pulmonary 
bypass 
Randomized 
double-blind 
0.05 
mcg/kg/min 
onset of 
CPB 
Milrinone 18 vs 18 No significant difference 
between serum lactate levels of 
groups.  
Rate-pressure index 
significantly lower in LS 
group at 24 and 48 h, 
indicating lower 
myocardialoxygen demand 
Tritapepe 
2006.32 
Patients undergoing 
elective CABG 
Randomized 
double-blind 
24 mcg/kg 
as a bolus in 
10 min 
Just before 
placing 
patient on 
CPB 
Placebo 12 vs. 12 Lower troponin I release 
(p<0.05) and a higher cardiac 
index (p<0.05) potoperatively 
 
Tritapepe 
2009.33 
Patients undergoing 
elective CABG 
Randomized 
double-blind 
24 mcg/kg 
as a bolus in 
10 min 
Just before 
placing 
patient on 
CPB 
Placebo 52 vs. 50 Length of ICU stay shorter in 
LS group: 
25(7) vs. 32 (13) hours; p=0.002 
 
Length of hospital 
Stay and  tracheal 
intubation time shorter in 
LS group. Troponin I 
release lower in LS group 
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Low EF Studies
AI-Shawaf 2006 1 14 1 16 2.6% 0.0089 (-0.1707, 0.1886)
Alvarez 2005 1 15 0 15 2.6% 0.0667 (-0.0997, 0.2330)
 1 25 1 25 4.3% 0.0000 (-0.1086, 0.1086)
De Hert 2007 0 15 3 15 2.6% -0.2000 (-0.4198, 0.0198)
Eriksson 2009 0 30 2 30 5.2% -0.0667 (-0.1723, 0.0389)
Levin 2009 9 127 20 126 21.9% -0.0879 (-0.1657, -0.0100)
Levin2012 5 127 16 125 21.8% -0.0886 (-0.1563, -0.0210)
Lomivorotov 2011 0 20 0 20 3.5% 0.0000 (-0.0922, 0.0922)
Subtotal (95%CI)  373  372 64.5% -0.0702 [-0.1099, -0.0306]
Total Events  17  43
2 2Heterogenecity: Chi  = 9.01, df = 7 (P=0.25); I =22%
Test for overall effect: Z = 3.47 (P=0.0005)
Preserved EF Studies
Jarvela 2008 1 12 0 12 2.1% 0.0833 (-0.1194, 0.2860)
Lahtinen 2011 10 99 10 101 17.3% 0.0020 9-0.0812, 0.0852)
Leppikangas 2011 1 12 0 12 2.1% 0.0833 (-0.1194, 0.2860)
Momeni 2011 1 18 1 18 3.1% 0.0000 (-0.1497, 0.1497)
Tritapepe 2006 0 12 0 12 2.1% 0.0000 (-0.1478, 0.1478)
Tritapepe 2009 0 52 0 50 8.8% 0.0000 (-0.0375, 0.0375)
Subtotal (95% CI)  205  205  35.5% 0.0107 [-0.0375, 0.0590]
Total events 13 11
Heterogenecity: 
Total (95%CI)  578  577  100.0% -0.0415 [-0.0723, -0.0107]
Total events 30 54
2 2Heterogenecity: Chi =17.96, df=13 (P=0.16); I =28%
Test for overall effect: Z=2.64 (P=0.008)
2 2Test for subgroup differences: Chi =6.45, df=1 (P=0.01), I =84.5%
Alvarez 2006
2 2Chi  = 1.38, df = 5 (P=0.93); I = 0%
Test for overall effect: Z = 0.44 (P=0.66)
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Primary outcomes
30-days mortality 4 972 18 490 28 482 0.64 0.36 - 1.16 0 0.14
Longterm morality 3 1134  29 572 51 562 0.57 0.36 - 0.90 2 0.01
Clinical Out comes No. of 
studies
No. of 
patients
Levosimendan
Total Total
Control
Events Events
Risk ratio (M-H, random effect) Risk ratio (M-H, 
random effect)
95%, CI 2I (%) p value
-2   -1.5   -1  -0.5    0     0.5   1    1.5    2    2.5
Levosimendan Control
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